PubMed 12955872 Staron RS, et al
Your individual genetic profile, as revealed by the PlexusDx Precision Peptide Genetic Test, can help describe the pathway-level variants involved
Notably, this study included broad range of GLP-1 drugs, including much older GLP-1s that have far lower anti-obesity, anti-craving, and anti-addictive effects: abiglutide (Eperzan, Tanzeum), dulaglutide (Trulicity), exenatide (Byetta, Bydureon), liraglutide (Victoza, Saxenda), lixisenatide (Adlyxin, Lyxumia), semaglutide (Ozempic, Rybelsus, Wegovy) and tirzepatide (Mounjaro) Its possible that the associations that were found would be even stronger if the study had looked exclusively at semaglutide and tirzepatide, which are the current best-in-class options for weight loss
SKU: FOU-FDF0H6